BioMarin Pharmaceutical Inc. $BMRN Stock: ARGA Investment Management LP Trims Stake

ARGA Investment Management LP trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 29.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 737,541 shares of the biotechnology company's stock after selling 301,868 shares during the quarter. BioMarin Pharmaceutical comprises about 1.1% of ARGA Investment Management LP's investment portfolio, making the stock its 20th largest holding. ARGA Investment Management LP owned approximately 0.38% of BioMarin Pharmaceutical worth $44,252,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Parkside Financial Bank & Trust grew its holdings in BioMarin Pharmaceutical by 70.3% in the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 187 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of BioMarin Pharmaceutical during the second quarter worth $39,000. Keating Financial Advisory Services Inc. acquired a new position in shares of BioMarin Pharmaceutical during the second quarter worth $56,000. Root Financial Partners LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter valued at $88,000. Finally, Parallel Advisors LLC lifted its holdings in shares of BioMarin Pharmaceutical by 33.9% during the 1st quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 448 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Stock Down 3.1%

BMRN opened at $55.66 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The company has a fifty day moving average of $60.24 and a two-hundred day moving average of $58.45. The stock has a market capitalization of $10.77 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 0.63 and a beta of 0.21.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.59%. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the company earned $0.12 EPS. The firm's revenue for the quarter was up 32.0% compared to the same quarter last year. On average, research analysts expect that BioMarin Pharmaceutical Inc. will post 2.59 earnings per share for the current year.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Third-quarter revenue rose 32% year over year to about $1.025 billion, in line with estimates, while non-GAAP EPS of $0.23 beat consensus expectations for a loss. Metabolic and skeletal-condition sales increased 44% and 12%, respectively. BioMarin Q3 results
• Positive Sentiment: BioMarin added an investigational Fabry-disease asset to its pipeline, while VOXZOGO for hypochondroplasia has an FDA action date of May 30, 2027—potential longer-term growth catalysts. BioMarin Q3 results
• Neutral Sentiment: Analyst views were mixed: Morgan Stanley maintained an Overweight rating despite trimming its target to $119, while HC Wainwright reaffirmed Neutral with a $60 target. Morgan Stanley rating HC Wainwright rating
• Negative Sentiment: BioMarin’s 2026 EPS outlook of $2.80–$3.10 is below the $3.32 consensus. Revenue guidance of $3.8–$3.9 billion also falls short of the $3.9 billion estimate at the low end; the company cited uncertainty around order timing and two acquired IPR&D charges. 2026 guidance update
• Negative Sentiment: RBC lowered its price target from $62 to $60 and kept a Sector Perform rating. The target reductions from RBC and Morgan Stanley temper the positive implications of the quarterly beat. RBC rating

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Raymond James Financial raised BioMarin Pharmaceutical from an "outperform" rating to a "strong-buy" rating and set a $109.00 price objective for the company in a research report on Monday, October 12th. Royal Bank Of Canada reduced their target price on BioMarin Pharmaceutical from $62.00 to $60.00 and set a "sector perform" rating on the stock in a research report on Tuesday. JPMorgan Chase & Co. increased their price target on BioMarin Pharmaceutical from $86.00 to $87.00 and gave the company an "overweight" rating in a research note on Tuesday, October 20th. Canaccord Genuity Group increased their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a "buy" rating in a research note on Monday, August 10th. Finally, BMO Capital Markets reissued an "outperform" rating on shares of BioMarin Pharmaceutical in a report on Wednesday, September 16th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $87.96.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company's research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin's marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.